Efficacy
REMISSION
During follow-up of a median 5.5 months (range, 1–14 months), 11(92%) patients achieved drug-free remission, with no relapse with all corticosteroids and immunosuppressants discontinued,. Patient 1 had a possible attack of decreased visual acuity in the left eye at 14-month after infusion (Supplementary Fig. All patients showed decrease in the EDSS score from baseline at last follow-up (Fig. Functional improvement after CT103A infusion. 